Lipoprotein(a) Levels, Genotype, and Incident Aortic Va

Circulation: Cardiovascular Genetics
7, 304-310
DOI: 10.1161/circgenetics.113.000400

Citation Report

#	Article	IF	Citations
1	Valve Tissue Characterization by Magnetic Resonance Imaging in Calcific Aortic Valve Disease. Canadian Journal of Cardiology, 2014, 30, 1676-1683.	0.8	13
2	What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?. Current Opinion in Lipidology, 2014, 25, 423-430.	1.2	22
3	Calcific Aortic Valve Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2387-2393.	1.1	261
4	Lipid Interventions in Aortic Valvular Disease. American Journal of the Medical Sciences, 2015, 350, 313-319.	0.4	4
5	â€˜LDL-Câ€™â€Š=â€ŠLDL-Câ€Š+â€ŠLp(a)-C. Current Opinion in Lipidology, 2015, 26, 169-178.	1.2	122
6	What does the future hold for cholesteryl ester transfer protein inhibition?. Current Opinion in Lipidology, 2015, 26, 526-535.	1.2	1
7	Aortic Stenosis: Changing Disease Concepts. Journal of Cardiovascular Imaging, 2015, 23, 59.	0.8	36
8	Innate and Adaptive Immunity in Calcific Aortic Valve Disease. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	81
9	Genome-wide association studies of late-onset cardiovascular disease. Journal of Molecular and Cellular Cardiology, 2015, 83, 131-141.	0.9	42
10	Genetic Risk Factors and Mendelian Randomization in Cardiovascular Disease. Current Cardiology Reports, 2015, 17, 33.	1.3	11
11	HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a). Journal of Lipid Research, 2015, 56, 1241-1244.	2.0	2
12	Oxidized Phospholipids, Lipoprotein(a),Âand Progression of CalcificÂAortic ValveÂStenosis. Journal of the American College of Cardiology, 2015, 66, 1236-1246.	1.2	295
13	Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease. Circulation: Cardiovascular Genetics, 2015, 8, 812-822.	5.1	51
15	Mendelian randomisation applied to drug development in cardiovascular disease: a review. Journal of Medical Genetics, 2015, 52, 71-79.	1.5	52
16	Genetics of Coronary Disease. , 2016, , 81-101.		2
17	Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Current Opinion in Cardiology, 2016, 31, 440-450.	0.8	55
18	Structure, function, and genetics of lipoprotein (a). Journal of Lipid Research, 2016, 57, 1339-1359.	2.0	352
19	Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. Journal of Internal Medicine, 2016, 280, 509-517.	2.7	73

#	Article	IF	Citations
20	Lipoprotein(a) and risk of sudden cardiac death in middle-aged Finnish men: A new prospective cohort study. International Journal of Cardiology, 2016, 220, 718-725.	0.8	28
21	Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis. G3: Genes, Genomes, Genetics, 2016, 6, 3525-3532.	0.8	7
22	Genetics of Lipid and Lipoprotein Disorders and Traits. Current Genetic Medicine Reports, 2016, 4, 130-141.	1.9	61
23	Heart valve health, disease, replacement, and repair: a 25-year cardiovascular pathology perspective. Cardiovascular Pathology, 2016, 25, 341-352.	0.7	30
24	Lipoprotein (a): a promising target in the treatment of stenotic valvular diseases. European Heart Journal Cardiovascular Imaging, 2016, 17, 498-499.	0.5	0
25	Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1003-1009.	1.1	63
26	Lipoprotein(a) Interactions With Lowâ€Ðensity Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS). Journal of the American Heart Association, 2016, 5, .	1.6	63
27	PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3281-3287.	1.8	89
28	Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Journal of Lipid Research, 2016, 57, 1953-1975.	2.0	365
29	The re-emergence of lipoprotein(a) in a broader clinical arena. Progress in Cardiovascular Diseases, 2016, 59, 135-144.	1.6	24
30	Lp(a) and cardiovascular risk: Investigating the hidden side of the moon. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 980-986.	1.1	39
31	Medical Treatment of Aortic Stenosis. Circulation, 2016, 134, 1766-1784.	1.6	113
32	Lipoprotein(a): Revisiting a Next Therapeutic Target. Circulation Journal, 2016, 80, 329-331.	0.7	2
33	The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis. Current Atherosclerosis Reports, 2016, 18, 82.	2.0	157
34	Calcific aortic stenosis. Nature Reviews Disease Primers, 2016, 2, 16006.	18.1	568
35	Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. JACC: Heart Failure, 2016, 4, 78-87.	1.9	106
36	Circulating Lp-PLA2 is associated with high valvuloarterial impedance and low arterial compliance in patients with aortic valve bioprostheses. Clinica Chimica Acta, 2016, 455, 20-25.	0.5	3
37	Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis. Cardiovascular Drugs and Therapy, 2016, 30, 75-85.	1.3	31

#	Article	IF	Citations
38	Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. Cardiovascular Drugs and Therapy, 2016, 30, 87-100.	1.3	165
39	Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis. Journal of Lipid Research, 2016, 57, 917-924.	2.0	75
40	Cardiovascular disease prevention: lifestyle attenuation of genetic risk. Nature Reviews Cardiology, 2017, 14, 187-188.	6.1	5
41	A Test in Context: Lipoprotein(a). Journal of the American College of Cardiology, 2017, 69, 692-711.	1.2	668
42	Overall and abdominal obesity and incident aortic valve stenosis: two prospective cohort studies. European Heart Journal, 2017, 38, 2192-2197.	1.0	78
43	Does lifestyle contribute to disease severity in patients with inherited lipid disorders?. Current Opinion in Lipidology, 2017, 28, 177-185.	1.2	15
44	Lipoprotein(a): new insights from modern genomics. Current Opinion in Lipidology, 2017, 28, 170-176.	1.2	22
45	OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoAâ€“NF-ÎºB pathway. Cardiovascular Research, 2017, 113, 1351-1363.	1.8	76
46	The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis, 2017, 262, 131-137.	0.4	29
47	Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1570-1578.	1.1	60
48	Incidence of elevated lipoproteinÂ(a) levels in aÂlarge cohort of patients with cardiovascular disease. Clinical Research in Cardiology Supplements, 2017, 12, 55-59.	2.0	11
49	A Replicated, Genome-Wide Significant Association of Aortic Stenosis With a Genetic Variant for Lipoprotein(a). Circulation, 2017, 135, 1181-1183.	1.6	45
50	Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis, 2017, 260, 1-7.	0.4	6
51	Do Oxidized Lipoproteins Cause Atherosclerotic Cardiovascular Diseases?. Canadian Journal of Cardiology, 2017, 33, 1513-1516.	0.8	2
52	Evaluation of Lipoprotein(a) Electrophoretic and Immunoassay Methods in Discriminating Risk of Calcific Aortic Valve Disease and Incident Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis. Clinical Chemistry, 2017, 63, 1705-1713.	1.5	20
53	High Lipoprotein(a) and Low Risk of Major Bleeding in Brain and Airways in the General Population: a Mendelian Randomization Study. Clinical Chemistry, 2017, 63, 1714-1723.	1.5	31
54	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. Progress in Lipid Research, 2017, 68, 57-82.	5.3	63
55	Pathobiology of Lp(a) in calcific aortic valve disease. Expert Review of Cardiovascular Therapy, 2017, 15, 797-807.	0.6	23

#	Article	IF	Citations
56	Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. Atherosclerosis, 2017, 256, 47-52.	0.4	65
57	Lipoprotein(a) and the Apolipoprotein B/A1 Ratio Independently Associate With Surgery for Aortic Stenosis Only in Patients With Concomitant Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	1.6	23
58	Genome-wide analysis yields new loci associating with aortic valve stenosis. Nature Communications, 2018, 9, 987.	5.8	91
59	Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 33-54.	2.7	20
60	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated RiskÂofÂCardiovascular Disease and AorticÂStenosis. Journal of the American College of Cardiology, 2018, 71, 177-192.	1.2	337
61	ApoB/ApoAâ€‰Ratio is Associated With Faster Hemodynamic Progression of Aortic Stenosis: Results From the PROGRESSA (Metabolic Determinants of the Progression of Aortic Stenosis) Study. Journal of the American Heart Association, 2018, 7, .	1.6	10
62	The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?. Current Opinion in Lipidology, 2018, 29, 259-267.	1.2	11
63	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. Journal of Clinical Lipidology, 2018, 12, 130-136.	0.6	44
64	Relation of an Echocardiographic-Based Cardiac Calcium Score to Mitral Stenosis Severity and Coronary Artery Disease in Patients with Severe Aortic Stenosis. American Journal of Cardiology, 2018, 121, 249-255.	0.7	3
65	Blood, tissue and imaging biomarkers in calcific aortic valve stenosis. Current Opinion in Cardiology, 2018, 33, 125-133.	0.8	16
66	Association of LPA Variants With Aortic Stenosis. JAMA Cardiology, 2018, 3, 18.	3.0	46
67	OBSOLETE: Genetic Disorders Involving Valve Function. , 2018, , .		0
68	Degenerative Aortic Stenosis, Dyslipidemia and Possibilities of Medical Treatment. Medicina (Lithuania), 2018, 54, 24.	0.8	13
69	Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2498-2504.	1.1	35
70	Involvement of inflammatory responses in the early development of calcific aortic valve disease: lessons from statin therapy. Animal Cells and Systems, 2018, 22, 390-399.	0.8	16
71	Advances in Pathophysiology of Calcific Aortic Valve Disease Propose Novel Molecular Therapeutic Targets. Frontiers in Cardiovascular Medicine, 2018, 5, 21.	1.1	44
72	Precision Medicine for ProstheticÂValveÂDeterioration. Journal of the American College of Cardiology, 2018, 72, 252-254.	1.2	1
73	Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments. Pharmacological Research, 2018, 136, 74-82.	3.1	41

#	Article	IF	Citations
74	Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease. Atherosclerosis, 2018, 277, 60-65.	0.4	89
75	apoB/apoAâ€‰Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPICâ€‰Norfolk Prospective Population Study. Journal of the American Heart Association, 2019, 8, e013020.	1.6	18
76	The Future of Lipid-lowering Therapy. Journal of Clinical Medicine, 2019, 8, 1085.	1.0	8
77	Elevated Lipoprotein(a) and RiskÂofÂIschemic Stroke. Journal of the American College of Cardiology, 2019, 74, 54-66.	1.2	131
78	Heart valve calcification. , 2019, , 307-319.		0
79	Lipoprotein(a) Gene Polymorphism Increases a Risk Factor for Aortic Valve Calcification. Journal of Cardiovascular Development and Disease, 2019, 6, 31.	0.8	10
80	Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis. Circulation Research, 2019, 124, 405-415.	2.0	57
81	Potential Role of H-Ferritin in Mitigating Valvular Mineralization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 413-431.	1.1	24
82	Development of calcific aortic valve disease: Do we know enough for new clinical trials?. Journal of Molecular and Cellular Cardiology, 2019, 132, 189-209.	0.9	68
83	Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification. JAMA Cardiology, 2019, 4, 620.	3.0	32
84	The rs10455872-G allele of the LPA gene is associated with high lipoprotein(a) levels and increased aortic valve calcium in a Mexican adult population. Genetics and Molecular Biology, 2019, 42, 519-525.	0.6	6
85	Antisense Oligonucleotides Targeting Lipoprotein(a). Current Atherosclerosis Reports, 2019, 21, 30.	2.0	38
86	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2019, 13, 374-392.	0.6	315
87	LPA genotype is associated with premature cardiovascular disease in familial hypercholesterolemia. Journal of Clinical Lipidology, 2019, 13, 627-633.e1.	0.6	15
88	Whatâ€™s new on therapies for elevated lipoprotein(a). Expert Review of Clinical Pharmacology, 2019, 12, 495-499.	1.3	0
89	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With AorticÂStenosis. Journal of the American College of Cardiology, 2019, 73, 2150-2162.	1.2	187
90	Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography. CJC Open, 2019, 1, 131-140.	0.7	38
91	Autotaxin and Lipoprotein Metabolism in Calcific Aortic Valve Disease. Frontiers in Cardiovascular Medicine, 2019, 6, 18.	1.1	20

#	Article	IF	Citations
92	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry, 2019, 56, 338-356.	0.8	27
93	To test, or not to test: that is the question for the future of lipoprotein(a). Expert Review of Cardiovascular Therapy, 2019, 17, 241-250.	0.6	4
94	Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region. Clinical Research in Cardiology Supplements, 2019, 14, 5-12.	2.0	31
95	Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction. Circulation Journal, 2019, 83, 1047-1053.	0.7	11
96	Targeting the autotaxin â€“ Lysophosphatidic acid receptor axis in cardiovascular diseases. Biochemical Pharmacology, 2019, 164, 74-81.	2.0	40
97	Lp(a) and cardiovascular diseaseâ€”Has the phoenix finally risen from the ashes?. European Heart Journal, 2019, 40, 2771-2774.	1.0	5
98	Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis. Biomolecules, 2019, 9, 760.	1.8	26
99	PALMD as a novel target for calcific aortic valve stenosis. Current Opinion in Cardiology, 2019, 34, 105-111.	0.8	6
100	Risk factors for valvular calcification. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 96-102.	1.2	39
101	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. Journal of Clinical Medicine, 2019, 8, 2073.	1.0	15
102	Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 281, 25-30.	0.4	31
103	Lipoprotein(a) catabolism: a case of multiple receptors. Pathology, 2019, 51, 155-164.	0.3	79
104	Dietary patterns, food groups, and incidence of aortic valve stenosis: A prospective cohort study. International Journal of Cardiology, 2019, 283, 184-188.	0.8	14
105	Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis. International Journal of Cardiology, 2019, 276, 212-217.	0.8	9
106	High lipoprotein(a) and high risk of mortality. European Heart Journal, 2019, 40, 2760-2770.	1.0	149
107	Calcific Aortic Valve Stenosis and Atherosclerotic Calcification. Current Atherosclerosis Reports, 2020, 22, 2.	2.0	29
108	Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy. Cardiology Clinics, 2020, 38, 1-12.	0.9	43
109	Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis. JACC Basic To Translational Science, 2020, 5, 888-897.	1.9	15

#	Article	IF	Citations
110	The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives. Hellenic Journal of Cardiology, 2020, 61, 398-403.	0.4	15
111	Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?. Nutrients, 2020, 12, 2024.	1.7	40
112	Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Lowâ€Ðensity Lipoprotein Cholesterolâ€"The Framingham Heart Study. Journal of the American Heart Association, 2020, 9, e014711.	1.6	22
113	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiology, 2020, 5, 709.	3.0	63
114	Plasma lipoprotein(a) concentration as an independent predictor of hemodynamic progression of aortic valve stenosis. Molecular and Cellular Biochemistry, 2020, 472, 199-207.	1.4	4
115	Lipoprotein(a) and calcific aortic valve stenosis: A systematic review. Progress in Cardiovascular Diseases, 2020, 63, 496-502.	1.6	21
116	Vascular and valvular calcification biomarkers. Advances in Clinical Chemistry, 2020, 95, 73-103.	1.8	29
117	Aortic valve calcification in the era of non-coding RNAs: The revolution to come in aortic stenosis management?. Non-coding RNA Research, 2020, 5, 41-47.	2.4	10
118	Genetic and InÂVitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis. JACC Basic To Translational Science, 2020, 5, 649-661.	1.9	45
119	Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans. Heart, 2020, 106, 1407-1412.	1.2	12
120	Conceptualization of Heterogeneity of Chronic Diseases and Atherosclerosis as a Pathway to Precision Medicine: Endophenotype, Endotype, and Residual Cardiovascular Risk. International Journal of Chronic Diseases, 2020, 2020, 1-9.	1.9	10
121	Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Diseaseâ€"Free Survival, and Mortality Risk. JAMA Network Open, 2020, 3, e200129.	2.8	27
122	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. American Journal of Cardiology, 2020, 126, 94-102.	0.7	25
123	Lipoprotein(a) and Cardiovascular Diseasesã€€â€• Revisited â€•. Circulation Journal, 2020, 84, 867-874.	0.7	40
124	Lipoprotein(a): Expanding our knowledge of aortic valve narrowing. Trends in Cardiovascular Medicine, 2021, 31, 305-311.	2.3	13
125	Lipoprotein(a) and Cardiovascular Disease. Clinical Chemistry, 2021, 67, 154-166.	1.5	107
126	Menaquinone 4 increases plasma lipid levels in hypercholesterolemic mice. Scientific Reports, 2021, 11, 3014.	1.6	3
127	Role of inflammation, autotaxin and lipoprotein (a) in degenerative aortic valve stenosis in patients with coronary artery disease. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2598.	0.4	2

#	Article	IF	Citations
128	Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Cardiovascular Research, 2022, 118, 1218-1231.	1.8	30
129	Role of oxidative stress in calcific aortic valve disease and its therapeutic implications. Cardiovascular Research, 2022, 118, 1433-1451.	1.8	33
130	Lipoprotein(a) is robustly associated with aortic valve calcium. Heart, 2021, 107, 1422-1428.	1.2	29
131	Diabetes Mellitus and Its Implications in Aortic Stenosis Patients. International Journal of Molecular Sciences, 2021, 22, 6212.	1.8	7
132	Drugs for Prevention and Treatment of Aortic Stenosis: How Close Are We?. Canadian Journal of Cardiology, 2021, 37, 1016-1026.	0.8	9
133	The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?. Current Cardiology Reports, 2021, 23, 97.	1.3	10
134	Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis. Metabolites, 2021, 11, 459.	1.3	14
135	Lipoprotein (a): When to Measure and How to Treat?. Current Atherosclerosis Reports, 2021, 23, 51.	2.0	18
136	Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. Atherosclerosis, 2022, 349, 211-218.	0.4	12
137	Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. Heart, 2022, 108, 61-66.	1.2	18
138	Valve Calcification (Aortic and Mitral). , 2022, , 45-63.		0
139	Metabolomic Signature of Human Aortic Valve Stenosis. JACC Basic To Translational Science, 2020, 5, 1163-1177.	1.9	12
140	Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. European Heart Journal, 2022, 43, 683-697.	1.0	76
141	Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. European Journal of Preventive Cardiology, 2022, 29, 779-792.	0.8	47
142	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, ATV0000000000000147.	1.1	207
143	Genetic Disorders Involving Valve Function. , 2018, , 313-326.		0
147	Lipoprotein(a) and aortic valve stenosis: A casual or causal association?. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 309-317.	1.1	7
148	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. Contemporary Cardiology, 2021, , 615-636.	0.0	0

#	Article	IF	Citations
149	The Role of Genetics in Preventive Cardiology: Utility of Clinically Available Genetic Tests. Contemporary Cardiology, 2021, , 335-364.	0.0	0
150	Correlation Between Plasma Matrix Metalloproteinase-28 Levels and Severity of Calcific Aortic Valve Stenosis. Medical Science Monitor, 2020, 26, e925260.	0.5	2
151	Lipids in Children and Links to Adult Vascular Disease. Clinical Biochemist Reviews, 2018, 39, 65-76.	3.3	5
152	Association of serum lipoprotein(a) level with the severity and prognosis of calcific aortic valve stenosis: a Chinese cohort study. Journal of Geriatric Cardiology, 2020, 17, 133-140.	0.2	4
153	Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: The Copenhagen General Population Study. Atherosclerosis, 2022, 349, 166-174.	0.4	21
154	Lipoprotein(a). Handbook of Experimental Pharmacology, 2021, , 201-232.	0.9	22
155	Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in Cardiovascular Diseases, 2022, 73, 32-40.	1.6	19
156	Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et al. Heart, 2022, 108, 576-577.	1.2	0
157	Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease. Frontiers in Cell and Developmental Biology, 2022, 10, 812368.	1.8	5
158	Impact of Fetuin-A, Lp(a), matrix gla protein and macrophage density on calcific aortic valve disease: a clinical study. Lipids in Health and Disease, 2022, 21, 14.	1.2	2
159	Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. Atherosclerosis, 2022, 349, 144-150.	0.4	9
160	Immune Response and Lipid Metabolism Gene Polymorphisms Are Associated with the Risk of Obesity in Middle-Aged and Elderly Patients. Journal of Personalized Medicine, 2022, 12, 238.	1.1	7
161	Lipoprotein(a) and Body Mass Compound the Risk of Calcific Aortic Valve Disease. Journal of the American College of Cardiology, 2022, 79, 545-558.	1.2	12
162	Perspective Chapter: Lipoprotein (a), Cardiac Amyloidosis, and Aortic Stenosis - Underestimated Associations. , 0, , .		0
163	Plasma Lipoprotein(a) measured in routine clinical care and the association with incident calcified aortic valve stenosis during a 14-year observational period. Atherosclerosis, 2022, 349, 175-182.	0.4	7
164	Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart, 2023, 109, 18-25.	1.2	15
165	Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic. Atherosclerosis, 2022, 349, 227-232.	0.4	39
166	Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis, 2022, 349, 240-247.	0.4	30

#	Article	IF	Citations
167	Lipoprotein(a)â€"The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation. Biomolecules, 2022, 12, 26.	1.8	31
168	Body Mass Index and Mortality from Nonrheumatic Aortic Valve Disease among Japanese Men and Women. Journal of Atherosclerosis and Thrombosis, 2022, , .	0.9	0
170	Association Between Lipoprotein(a) and Calcific Aortic Valve Disease: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 877140.	1.1	10
171	Lipoprotein(a) and its Significance in Cardiovascular Disease. JAMA Cardiology, 2022, 7, 760.	3.0	82
172	Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?. Basic Research in Cardiology, 2022, 117, 28.	2.5	9
173	Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective. Atherosclerosis, 2022, 349, 7-16.	0.4	54
174	Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?. Journal of Clinical Medicine, 2022, 11, 3331.	1.0	2
175	Considerations for routinely testing for high Lp(a). Current Opinion in Lipidology, 2022, 33, 213-218.	1.2	4
176	The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications. Theranostics, 2022, 12, 5189-5203.	4.6	5
177	Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification. European Heart Journal, 2022, 43, 3960-3967.	1.0	41
178	Considerations for routinely testing for high lipoprotein(a). Current Opinion in Lipidology, 0, Publish Ahead of Print, .	1.2	0
179	Lipoprotein(a) and aortic valve stenosis: work in progress. European Heart Journal, 2022, 43, 3968-3970.	1.0	8
180	Obesity, Triglycerides, Remnant Cholesterol, and Other Causal Factors in Aortic Valve Stenosis: A Review. Cardiometabolic Syndrome Journal, 2022, 2, 108.	1.0	1
181	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2022, 16, e77-e95.	0.6	16
182	Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 2022, 43, 3925-3946.	1.0	290
183	New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e4281-e4294.	1.8	5
184	Research Progress of Lipoprotein (a), Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio and Calcified Aortic Valve Disease. Advances in Clinical Medicine, 2022, 12, 9104-9110.	0.0	0
185	Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. Journal of Clinical Medicine, 2022, 11, 6040.	1.0	14

#	Article	IF	Citations
186	IL6 gene polymorphism association with calcific aortic valve stenosis and influence on serum levels of interleukin-6. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
187	Lipoprotein(a) and Calcific Aortic Valve Stenosis. EMJ Cardiology, 0, , 89-97.	0.0	0
188	Lipoprotein (a) Levels and Abdominal Aortic Aneurysm. A Systematic Review and Meta-analysis. Current Pharmaceutical Design, 2022, 28, 3492-3499.	0.9	7
189	Serum lipoprotein(a) and bioprosthetic aortic valve degeneration. European Heart Journal Cardiovascular Imaging, 2023, 24, 759-767.	0.5	1
190	Atherosclerosis Calcification: Focus on Lipoproteins. Metabolites, 2023, 13, 457.	1.3	4
191	Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis. European Journal of Epidemiology, 2023, 38, 485-499.	2.5	12
192	Lipoprotein(a): Its Association with Calcific Aortic Valve Stenosis, the Emerging RNA-Related Treatments and the Hope for a New Era in â€œTreatingâ€•Aortic Valve Calcification. Journal of Cardiovascular Development and Disease, 2023, 10, 96.	0.8	2
193	Calcific aortic valve disease: mechanisms, prevention and treatment. Nature Reviews Cardiology, 2023, 20, 546-559.	6.1	22
194	Lp(a) and Aortic Valve Stenosis, Stroke, and Other Noncoronary Cardiovascular Diseases. Contemporary Cardiology, 2023, , 241-250.	0.0	0
195	Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis. Diseases (Basel, Switzerland), 2023, 11, 43.	1.0	0
196	C-reactive protein in people with high lipoprotein a: a partner in crime or an innocent bystander?. European Heart Journal, 2023, 44, 1461-1463.	1.0	2
197	Medical Therapy to Prevent or Slow Progression of Aortic Stenosis: Current Evidence and Future Directions. Cardiology in Review, 0, Publish Ahead of Print, .	0.6	1
198	Impact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression. European Heart Journal Open, 2023, 3, .	0.9	3
199	Prevalence of Polymorphisms of Genes Responsible for Coagulation System and Folate Metabolism and Their Predictive Value for Thrombosis Development in MINOCA Patients: Immediate and Long-Term Prognoses. Neurology International, 2023, 13, 47-60.	0.2	1
200	Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study. European Heart Journal, 2023, 44, 1927-1939.	1.0	19
201	Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis. Cardiovascular Research, 2023, 119, 1641-1655.	1.8	4